Victorian Clinical Genetics Services

What Victorian Clinical Genetics Services does

Victorian Clinical Genetics Services (VCGS) is an Australian not-for-profit specialist laboratory and clinical genetics service that delivers comprehensive genetic testing, genetic counselling, and clinical genetics services to patients, families, and health professionals. The organisation operates as a subsidiary of the Murdoch Children's Research Institute (MCRI) and is physically co-located at The Royal Children's Hospital in Parkville, Melbourne, with clinical outreach across regional Victoria and the Northern Territory. Founded in 1988, VCGS reports a headcount of 251-500 staff, including Principal Clinical Geneticists, Principal Genetic Counsellors, a Head of Clinical Bioinformatics, and a Chair of Genomic Medicine. The organisation reinvests proceeds from testing into medical research conducted by MCRI.

The core service portfolio spans the full genetic testing continuum: non-invasive prenatal screening (percept NIPT), carrier screening (prepair 3/500+/1000+), maternal serum screening, government-funded newborn bloodspot screening, and clinical genomic sequencing including exome and whole genome sequencing (WGS). Underlying technology combines next-generation sequencing, customised bioinformatics, biochemistry-based screening, and a phenotype-driven analytical approach. From 4 May 2025, WGS was positioned as the primary test option at pricing equivalent to exome sequencing. In 2026, VCGS co-developed Talos, an open-source automated reanalysis tool that reinterprets stored genomic data to detect rare diseases, achieving a 5.1% additional diagnostic yield in 4,735 previously undiagnosed patients at under USD$12 per 1,000 genomes, with results published in Nature Medicine in collaboration with the Broad Institute, Microsoft Research, and the Centre for Population Genomics.

VCGS runs a sales-led, referral-driven go-to-market: health professionals order tests via online or paper forms, samples are collected at VCGS-affiliated sites, and results are returned to the referring physician. Pricing is publicly disclosed and follows a one-time-per-test model (percept NIPT $475 AUD; combined first trimester screening $135-$154 AUD; WGS priced at exome-equivalent rates), with Medicare rebates available for specified tests and the newborn bloodspot screening program funded by the Victorian Department of Health. Integration with Best Practice, Medical Director, and Genie practice management software supports clinician-side workflows, and from late 2026, results will flow into Australia's My Health Record by default.

Name

Victorian Clinical Genetics Services

Legal name

Victorian Clinical Genetics Services

Website

https://www.vcgs.org.au

Company type

Private

Founded year

1988

Operating status

Operating

Headcount range

251–500 employees

Short description

Victorian Clinical Genetics Services (VCGS) is an Australian not-for-profit clinical genetics laboratory that provides prenatal screening, carrier screening, newborn screening, and genomic sequencing to patients, families, and health professionals across Victoria and the Northern Territory.

Ownership category

akta.pro rank

Product category

Clinical Genetic Testing Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Genetic & Prenatal Testing Laboratories (HLAFAMAH)

akta.pro secondary industries

Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ), Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Genetic Counseling & Prenatal Testing Telehealth (carrier screening, NIPT counseling) (HLALAHAK)

Keywords

• Clinical genetic testing
• Prenatal screening services
• Newborn screening program
• Genomic sequencing services
• Carrier screening

Headquarters

HQ city

Parpeville

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Clinical Genetic Testing Services: Revenue generated from comprehensive genetic testing services including NIPT, carrier screening, genomic sequencing, and newborn screening. As a not-for-profit, proceeds support medical research.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

VCGS delivers clinical genetic and genomic testing services across prenatal screening (NIPT, maternal serum screening), carrier screening, newborn screening, and clinical genomic sequencing (exome and whole genome), supported by in-house laboratory analysis, expert clinical interpretation by geneticists and genetic counsellors, and the proprietary Talos automated reanalysis tool. Services are delivered to patients, families, and referring health professionals, primarily across Victoria and the Northern Territory.

Product overview

VCGS is a not-for-profit Australian provider of comprehensive genetic and genomic services. The portfolio includes prenatal screening (percept NIPT, maternal serum screening), carrier screening (prepair 3/500+/1000+), newborn screening, and clinical genomic sequencing (exome, WGS, and targeted tests). Services are delivered through a multidisciplinary team combining laboratory testing, clinical interpretation, and genetic counselling, with results uploaded to My Health Record. The recent Talos tool enables automated reanalysis of stored genomic data for rare disease detection.

Differentiator

Problem solved

Functional benefit

Products and services

• percept NIPT Non-invasive prenatal screening test that analyses cell-free fetal DNA using next-generation sequencing to estimate the chance of chromosome conditions such as Down syndrome. Designed for pregnant women, with results delivered to referring healthcare providers.
• prepair carrier screening Genetic carrier screening offered to individuals and couples considering pregnancy or in early pregnancy to determine their chance of having children with an inherited genetic condition. Includes prepair 3 (Medicare funded), prepair 500+, and prepair 1000+ panels.
• Maternal serum screening (MSS) Blood-based screening offered to pregnant women to assess risk of having a baby with Down syndrome, trisomy 18, or neural tube defects. Includes combined first trimester screening and second trimester screening options, with optional pre-eclampsia risk assessment.
• Newborn bloodspot screening (NBS) Population screening program for Victorian babies that identifies risk of rare but serious medical conditions using heel prick blood testing. Funded by the Victorian Department of Health and provided free to all Victorian babies.
• Genomic sequencing Clinical genomic sequencing services including exome sequencing and whole genome sequencing (WGS) to help identify causes of health and developmental problems using a phenotype-driven approach. WGS is offered at reduced pricing equivalent to exome sequencing costs.
• Talos automated reanalysis Open-source genomic tool developed with MCRI, Centre for Population Genomics, Broad Institute, and Microsoft Research that automatically reanalyses stored DNA data to detect rare diseases. Delivers an additional 5.1% diagnostic yield at less than USD$12 per 1,000 genomes, with a median 32-day time from reanalysis to clinical benefit.
• Genetic counselling services Genetic counselling services provided by trained counsellors to support patients and families before and after genetic testing, including reproductive and prenatal counselling.
• Clinical genetics clinics In-person clinical genetics consultations delivered at The Royal Children's Hospital in Melbourne, across regional Victoria, and in the Northern Territory, by consultant clinical geneticists and genetic counsellors.

Quantifiable outcome

• 5.1% additional diagnostic yield through automated reanalysis

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability4 records

Feature4 records

Partnerships

Five partnerships are on record, tiered core.

• Murdoch Children's Research Institute (MCRI)coreStrategic or Co-development PartnerMCRI is the parent organisation of VCGS. Research collaboration includes the Talos automated reanalysis tool development, where VCGS participated alongside MCRI in research published in Nature Medicine.
• Broad InstitutecoreStrategic or Co-development PartnerCollaborated in research led by MCRI to develop the Talos open-source genomic tool for automated reanalysis of stored DNA data for rare disease detection.
• Microsoft ResearchcoreTechnology or IntegrationCollaborated in research led by MCRI to develop the Talos open-source genomic tool. Contributed technical expertise to the automated reanalysis platform.
• Centre for Population GenomicscoreStrategic or Co-development PartnerCollaborated with VCGS and other partners in research to develop and validate the Talos automated reanalysis tool across US and Australian cohorts.
• The Royal Children's Hospital (RCH)coreStrategic or Co-development PartnerVCGS is located at The Royal Children's Hospital in Melbourne. The hospital provides clinical facilities and patient access for VCGS genetics clinics.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Sonic Genetics: Australian genetic testing arm of Sonic Healthcare, offering NIPT, carrier screening and clinical genomics nationwide. Most direct Australian competitor to VCGS, competing for the same referring clinicians and patient population.
• Genome.One: Australian clinical genomics service operated by the Garvan Institute, providing whole genome and clinical genomic interpretation. Closest Australian peer in clinical WGS and rare disease diagnostics with research institute backing similar to VCGS/MCRI.
• Natera: US-based commercial leader in reproductive genetic testing (Panorama NIPT, Empower carrier screen) and oncology/genomics. Direct international competitor in NIPT and reproductive genetics with global commercial scale VCGS does not have.
• GeneDx: US clinical genomics laboratory specializing in rare disease exome and genome sequencing. Highly comparable in rare disease focus, phenotype-driven analysis approach and clinical interpretation depth overlapping with VCGS genomic sequencing services.
• Centogene: Germany-based rare disease diagnostics and genetic testing company offering exome, genome and biomarker testing. Comparable in rare disease focus and global clinical genomics positioning, though operating at broader geographic scale.

Broad incumbents

• Myriad Genetics: Established US genetic testing company with broad portfolio across hereditary cancer, reproductive health and pharmacogenomics. A larger incumbent in genetic testing offering overlapping prenatal and rare disease capabilities alongside a much wider test menu.
• Labcorp (formerly Invitae): Labcorp acquired Invitae's genetic testing assets, creating a large incumbent offering NIPT, carrier screening and rare disease panels. Comparable across most of VCGS's test menu but at much greater scale and broader geographic reach.
• Eurofins Genoma (Eurofins Genomics): European clinical genomics and NIPT provider within the broader Eurofins diagnostics network. Comparable prenatal and reproductive genetics offering combined with broader laboratory services footprint than VCGS.

Regional players

• PathWest Laboratory Medicine WA: Western Australia's public pathology network offering newborn screening and clinical genetics. Comparable as a state-funded public clinical laboratory and newborn screening operator, but serving a different Australian state than VCGS.

Emerging players

• Lifecodexx: European NIPT provider offering genome-wide non-invasive prenatal screening. Comparable in NIPT technology focus but smaller and more narrowly specialized than VCGS's full genetic testing portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/TeamVCGS
• Facebookfacebook.com/MurdochChildrensResearchInstitute

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Victorian Clinical Genetics Services